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Abstract
Introduction: Adult-onset growth hormone deficiency (AGHD) is usually the last 
deficiency to be substituted in hypopituitarism. In children with documented GH 
deficiency, treatment without delay is crucial for achieving optimal effects on growth 
and development. In adults, it is not known whether a delay in treatment initiation 
influences biochemical response and the favourable physiological effects resulting from 
GH replacement therapy (GHRT).
Methods: A total of 1085 GH-deficient adults from KIMS (Pfizer International Metabolic 
Database) were included, adequately replaced with all pituitary hormones except for 
GH at baseline. Patients were stratified by sex and age (20–50 years and ≥50 years) 
and subsequently divided into two groups below and above the median duration of 
unsubstituted AGHD for that subgroup. The median time of unsubstituted GHD for the 
total cohort was 2.53 years (P5 = 0.35, P95 = 24.42).
Results: Beneficial effects of 4 years of GHRT were observed on lipids and quality of life in 
all subgroups. A decrease in waist circumference was observed only in older (>50 years) 
patients. There was no difference in IGF-I SDS and in GH dose required to normalize 
IGF-I in patients with a duration of unsubstituted AGHD above or below the median. 
No relevant differences were found between the groups for anthropometric measures, 
cardiovascular risk factors and quality of life scores.
Conclusion: In contrast to GHD in children and adolescents, no difference could be 
established in treatment response between early or late initiation of GHRT in AGHD in 
terms of required GH dose, IGF-I, metabolic health and quality of life.
Introduction
Adult growth hormone deficiency (AGHD) is characterized 
by changes in body fat distribution with increased central 
adiposity, hyperlipidaemia, increased predisposition to 
atherogenesis and reduced bone remodelling activity. It 
is also associated with a reduced quality of life. AGHD is 
usually caused by pituitary adenomas, recently also termed 
pituitary neuroendocrine tumours (PitNETs) (1), or the 
consequences of treatment of these tumours, including 
surgery and/or irradiation. It therefore usually occurs in 
the context of additional features of hypopituitarism, 
compounding the clinical picture attributable to AGHD 
(2, 3). Available evidence shows benefit of GH replacement 
therapy (GHRT) on body composition, exercise capacity, 
bone health, several cardiovascular risk factors and quality 
of life (3, 4, 5). Pitfalls of GH and IGF-I assays and the 
recent upward adjustment of the normative IGF-I SD scores 
for the iSYS IGF-I assay make early recognition of AGHD 
increasingly difficult (6, 7, 8). It is not known whether 
these changes in SD scores and the likely association of 
delayed initiation of GHRT result in poorer outcomes.
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In paediatric growth hormone therapy, it is well 
known that age of treatment onset is predictive of final 
height outcome (9). In addition, it has been shown that 
growth acceleration during the first year is more marked 
in younger children (10, 11). In adults, we and others 
previously demonstrated that age and sex influence body 
composition, both with respect to the effects of GHD (12, 
13) and GHRT (14, 15).
Against this background, we studied whether there 
was a difference in response to GHRT between longer 
and shorter duration of unsubstituted AGHD in patients 
grouped by age and sex. We hypothesized that early 
initiation of GHRT in AGHD results in better responsiveness 
of the somatotrophic axis with higher increases in IGF-I, 
more favourable effects on metabolic health and better 
improvement of quality of life compared to late initiation.
Methods
Study population
The KIMS database (Pfizer International Metabolic 
Database) was used to study the effects of hypopituitarism 
on obesity. KIMS, initiated in 1994, is a pharmaco-
epidemiological multicentre survey of adult hypopituitary 
(GH deficient) patients treated with GH replacement 
therapy (Genotropin®) (16). Included were all patients 
with a known duration of confirmed AGHD, defined as a 
peak GH level less than 3 µg/L mainly indicated by insulin-
induced hypoglycaemia (in 76% of cases), but in other 
cases by a weaker GH stimulation test like the arginine (in 
9%), GHRH (in 6%), glucagon (in 1%), or other tests (in 
8%). Patients were adequately replaced with all pituitary 
hormones except for GH. Excluded were patients with a 
previous diagnosis of Cushing’s disease, acromegaly and 
craniopharyngioma because these conditions are known 
to affect body composition, cardiovascular risk factors 
and quality of life. For similar reasons of confounding 
bias, females reported to be on oestrogen and females who 
got pregnant during the study time frame were excluded. 
Finally, patients exposed to radiotherapy (RT) and patients 
with unknown treatment for diagnoses in which RT is an 
option were excluded, as it was not possible to determine 
the exact duration of AGHD in these patients. The patient 
population consisted of patients with isolated AGHD as 
well as multiple pituitary hormone deficiencies. Patients 
included in this study started GH replacement therapy at 
entry into KIMS and were in follow-up for an average time 
of 4.0 years (s.d. 0.2 years). Patients who did not complete 
4 years of follow-up were not included in the analyses.
With these criteria, a total of 1085 patients with 
hypopituitarism were identified for inclusion in the 
analysis. The KIMS countries (number of participants) 
for the present study were Argentina (12), Austria (19), 
Belgium (129), Switzerland (5), Czech Republic (31), 
Germany (304), Denmark (30), Spain (81), France (49) 
United Kingdom (97), Greece (7), Hungary (12), Ireland 
(12), Luxembourg (1), the Netherlands (81), Serbia (1), 
Sweden (184), Slovakia (9) and the United States (21).
Data were collected for KIMS at clinical visits 
on specially designed case record forms. The data 
collection process was externally monitored and audited. 
Demographic and clinical data related to pituitary 
and cardiovascular disease were used for the present 
analysis. The data collection into KIMS was approved 
by the Institutional Review Boards/Ethical Committees 
as required by local regulations in each participating 
country. Written informed consent was obtained from 
all patients before any data were entered into KIMS. The 
study was performed in accordance with The Declaration 
of Helsinki.
Estimated duration of unsubstituted AGHD
The estimated duration of unsubstituted AGHD was 
defined as time from the date of pituitary disease 
diagnosis as reported by local investigators to the date 
of entry into KIMS. In the rare event that the date of 
biochemical confirmation of AGHD was reported to be 
before the date of pituitary disease diagnosis, the date of 
biochemical confirmation was used. The median time of 
unsubstituted GHD for the total cohort was 2.53 years 
(P5 = 0.35, P95 = 24.42).
Stratification and definitions
Patients were stratified by sex and age (20–50 years and 
≥50 years) and subsequently divided into two groups below 
and above the median duration of unsubstituted AGHD 
for that subgroup. The age at which a patient entered 
KIMS was chosen for stratification. Thus, a complete data 
set together with anthropometric measures and laboratory 
determinations was guaranteed. A provisional diagnosis 
of diabetes was defined on a single fasting plasma glucose 
level of 7.0 mmol/L or higher according to the American 
Diabetes Association criteria (17) or the use of antidiabetic 
drugs. The Seventh Report of the Joint Committee on 
Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC 7) was used to define hypertension, 
i.e. a systolic blood pressure of more than 140 mmHg or 
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a diastolic blood pressure more than 90 mmHg or the 
use of antihypertensives (18).
Anthropometric measures
Height was measured with an accuracy of 0.5 cm and 
weight (in kilograms) to one decimal place. BMI was 
calculated from the formula: weight/height squared 
(kilograms per square meter). Waist circumference was 
measured in the supine position midway between the 
iliac crest and the lowest level of the thorax and hip as the 
maximal circumference. Blood pressure measurements in 
KIMS were standard office registrations.
Laboratory measurements
Measurements of serum total cholesterol (19), high-
density lipoprotein (HDL) cholesterol (20), and 
triglycerides (21) were performed by standard methods 
according to the KIMS protocol. Lipids were measured 
centrally and serum low-density lipoprotein (LDL) 
cholesterol was calculated using the Friedewald formula 
(22). Serum insulin-like growth factor I (IGF-I) was 
determined by RIA after acid/ethanol precipitation of 
IGF-binding proteins (Nichols Institute Diagnostics, San 
Juan Capistrano, CA, USA) until November 2002 and by 
chemiluminescence immunoassays from 2003 to 2004 
(Nichols Advantage® System) and from 2005 to 2012 
(Immulite 2500, DPC Siemens). For each assay, age- and 
gender-specific reference ranges were used to determine 
IGF-I SDS. Reference ranges and consistency of IGF-I SDS 
values between assays were validated internally. All above 
mentioned measurements were performed in a central 
laboratory. Glucose concentrations were measured in 
local participating centres. Whole blood concentrations 
were transformed to plasma values using an internally 
validated correction factor (23). All measurements 
including glucose were determined in fasting samples.
Quality of life assessment
Quality of life was assessed using the disease-specific 
Quality of Life Assessment of Growth Hormone Deficiency 
in Adults (QoL-AGHDA), a patient needs-based instrument 
developed specifically to detect deficits in areas that are 
affected in adults with GHD (24). The measure consists 
of 25 questions with ‘yes’ or ‘no’ response choices, 
with ‘yes’ answer indicating that the patient perceives a 
problem. The sum of ‘yes’ responses constitute a score, 
with a high score denoting a poor QoL. The QoL-AGHDA 
demonstrated satisfactory psychometric properties across 
a wide range of languages (25).
Statistical analysis
All calculations were performed with SAS (version 9.4, 
SAS Institute Inc.) or SPSS 22.0 (SPSS) software. Data are 
reported as mean ± s.d. or proportion, depending on type 
of variable. Males and females were analysed separately 
to avoid potential confounding by sex. For assessment 
of significance of mean differences between the patients 
below vs above the median for duration of unsubstituted 
AGHD, unpaired Student’s t-tests were performed. If 
variances were tested unequal between populations, 
Satterthwaite’s correction was applied. Comparisons of 
proportions were performed using the X2 test. A two-sided 
P value <0.05 was considered to be significant.
Results
Baseline characteristics
Baseline characteristics of the GH deficient patients 
are shown in Table 1. The mean estimated duration of 
unsubstituted AGHD for the total cohort was 6.0 years 
(s.d. 8.2 years), of which 1.7 years (s.d. 3.8 years) were 
biochemically confirmed. The most prevalent diagnosis 
was pituitary adenoma. Most patients received surgery 
as primary treatment and had multiple other pituitary 
hormone deficiencies. ADH deficiency was less common 
in patients aged >50 years. Male patients had more ACTH 
and LH/FSH deficiency than females. Male patients with 
a duration of unsubstituted AGHD below the median 
received surgical treatment more often and had a 
significantly higher IGF-I SDS at baseline than those above 
the median. However, no difference was found between 
these groups in GH dose required to normalize IGF-I. 
Table 2 shows anthropometric measures, cardiovascular 
risk factors and quality of life scores for both sexes in the 
two age groups of patients at baseline.
Adequacy of hormonal substitution
Between 97 and 99% of patients with TSH and ACTH 
deficiency received adequate hormonal substitution both 
at baseline and after 4 years of GHRT. More than 95% of 
LH/FSH deficient males were treated with testosterone 
throughout this observational study. The prevalence of 
other pituitary deficiencies did not change after 4 years of 
GHRT (data not shown).
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Effects of 4 years of GHRT
Beneficial effects of 4 years of GHRT were observed on 
lipids and quality of life in all subgroups. A decrease in 
waist circumference was observed only in older (>50 
years) patients. Changes in those measures after 4 years of 
GHRT are shown in Table 3.
Effects of early versus late initiation of GHRT
There was no difference in GH dose required to normalize 
IGF-I in patients with a duration of unsubstituted AGHD 
above or below the median. Additionally, IGF-I SDS did 
not differ between the early and late initiation groups 
after 4 years of GHRT.
Discussion
In this study, we investigated the effects of early versus 
late initiation of GHRT in adults with respect to GH dose, 
IGF-I, quality of life and metabolic health. Patients were 
grouped by age and sex, which are confounders known to 
influence the somatotrophic axis (12, 13). Four years of 
GHRT resulted in beneficial effects on lipids and quality 
of life in all cohorts. A decrease in waist circumference 
was observed only in the group of patients above 50 years 
of age. No differences were observed in GH dose required 
to normalize IGF-I between the groups with a duration 
of unsubstituted AGHD above or below the median. 
Additionally, IGF-I SDS did not differ between the groups 
after 4 years of GHRT. No relevant differences were 
found between the groups for anthropometric measures, 
cardiovascular risk factors and quality of life scores.
Our results are reassuring in relation to current clinical 
practice, in which AGHD is usually the last deficiency 
to be substituted in hypopituitarism. However, they are 
in contrast to the effects of paediatric growth hormone 
therapy, in which age of treatment onset is predictive 
of both growth acceleration during the first year and 
final height outcome (9). However, growth velocity in 
children is dependent on more hormonal and anabolic 
influences than GH per se, such as tempo of puberty and 
nutritional status.
For the initiation of postmenopausal oestradiol 
replacement therapy (ERT), it is now generally accepted 
that timing is critical; the sooner oestrogen is started 
after menopause, the greater the benefits (26, 27). 
These findings are presumed to be related to the health 
of the underlying tissue and/or to other factors such as 
downregulation of receptors (28, 29). Whether a similar 
mechanism could be present in AGHD has not previously 
been addressed. Serum GH and IGF-I decrease with age, 
peaking at late adolescence and declining from age 
20, resulting in considerably lower levels after age 60. 
This is likely to be the consequence of impaired signal 
transduction within the somatotrophic axis with age (30, 
31). However, the results of this study indicate that the 
timing hypothesis does not apply to the somatotrophic 
axis, as late initiation of GHRT in AGHD did not result 
in less responsiveness. Oestradiol is a steroid hormone 
binding primarily to oestrogen receptors, nuclear proteins 
that bind to DNA and control gene expression, whereas 
GH binds to the membrane-bound GH receptor, activating 
several intra- and intercellular signal transduction 
pathways (32). The regulation of these different classes of 
receptors is inherently different and may contribute to the 
different findings.
Our study is prone to several shortcomings. First, the 
estimated duration of unsubstituted AGHD was defined 
as time from the date of pituitary disease diagnosis as 
reported by local investigators to the date of entry into 
KIMS. In the rare event that the date of biochemical 
confirmation of AGHD was reported to be before the date 
of pituitary disease diagnosis, the date of biochemical 
confirmation was used. Both definitions are proxies, but 
the date of biochemical confirmation is most often an 
underestimation of the actual duration of unsubstituted 
AGHD. Although the use of the date of pituitary 
disease diagnosis as starting point likely results in an 
overestimation of the actual duration of unsubstituted 
AGHD, the large contrast between short and long duration 
of unsubstituted AGHD as reported in this study is crucial 
to its analysis and provides a solid basis for its conclusions. 
Although dates of pituitary disease diagnosis were entered 
retrospectively at entry into KIMS, they were based on 
medical records and checked by a monitor, reducing the 
risk of obtaining incorrect information.
Secondly, although appropriate for a large 
epidemiological study, the use of BMI and waist 
circumference alone is not optimal to characterize body 
composition. Data on fat mass, fat-free mass, and bone 
mass are, however, not available in KIMS. Thirdly, a 
selection bias may be present by the exclusion of patients 
with co-morbidities and diabetes, although in recent 
years more patients with co-morbidities and diabetes 
were considered for GH replacement therapy, possibly 
reflecting increased knowledge and confidence in GH 
therapy gained with time (33).
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Finally, one could argue that male patients below 
the median for duration of unsubstituted GHD receiving 
surgical treatment more often constitutes confounding by 
indication, as patients who receive surgical treatment are 
generally in follow-up according to protocol, are tested 
for hypopituitarism regularly and therefore have a higher 
chance to get GHRT early. However, this potential bias 
did not result in a difference between these groups in GH 
dose required to normalize IGF-I, nor in a difference in 
treatment response.
In conclusion, in contrast to GHD in children 
and adolescents, no difference could be established in 
treatment response between early or late initiation of 
GHRT in AGHD in terms of required GH dose, IGF-I, 
metabolic health and quality of life.
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